Targeting the E2F6-TOP2A-DKK1 axis: a novel therapeutic strategy for EMT-driven hepatocellular carcinoma progression - Takeaways - MDSpire

Targeting the E2F6-TOP2A-DKK1 axis: a novel therapeutic strategy for EMT-driven hepatocellular carcinoma progression

  • By

  • Mindan Xing

  • Yi Lu

  • Yan Guo

  • Yantao Jiang

  • Hengqi Liu

  • Junjie Yu

  • Luyao Tong

  • Zhongyu Wang

  • Chao Li

  • Xing Chen

  • Wei Luo

  • July 2, 2026

  • 0 min

Share

  • 1

    TOP2A is significantly upregulated in hepatocellular carcinoma (HCC) and correlates with advanced stage and poor survival outcomes.

  • 2

    A prognostic model incorporating TOP2A expression, TNM stage, and tumor grade demonstrated robust predictive accuracy for HCC survival.

  • 3

    E2F6 transcriptionally activates TOP2A, which in turn promotes epithelial-mesenchymal transition (EMT) by upregulating DKK1 and activating β-catenin signaling.

  • 4

    High TOP2A expression is associated with poor response to treatments such as transarterial chemoembolization (TACE) and sorafenib.

  • 5

    Targeting the E2F6-TOP2A-DKK1 pathway may provide a novel therapeutic strategy for treating HCC.

Original Source(s)

Related Content